EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retrospective analysis of outcomes for pediatric acute lymphoblastic leukemia in South American centers

Caitlyn Duffy, Dylan E Graetz, Arturo M Zapata Lopez, Angela K Carrillo, Godwin Job, Yichen Chen, Meenakshi Devidas, Sandra Alarcón Leon, Sol Aponte Bonzi, Pedro Cardona Flores, Lizeth Escobar Torres, Eddy Hernández Broncano und 9 weitere

Frontiers in Oncology · 30.10.2023 · 13

DOI: 10.3389/fonc.2023.1254233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 30.10.2023. Verfasst von Caitlyn Duffy und 20 weiteren Autor:innen. Beteiligte Einrichtung: St. Jude Children's Research Hospital, Department of Global Pediatric Medicine, Memphis, TN, United States. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acute lymphoblastic Leukemia (ALL) is the most common pediatric malignancy. While the survival rate for childhood ALL exceeds 90% in high-income countries, the estimated survival in low-and middle-income countries ranges from 22-79%, depending on the region and local resources.

Methods

This study retrospectively reviewed demographic, biological, and clinical parameters of children under 18 years of age with newly diagnosed ALL presenting between 2013-2017 across five pediatric centers in 4 countries in South America. Survival analyses were estimated using the Kaplan-Meier method.

Results

Across the five centers, 752 patients were analyzed (Bolivia [N=9], Ecuador [N=221], Paraguay [N=197], Peru [N=325]) and 92.1% (n=690) patients were diagnosed with B-cell and 7.5% (n= 56) with T-cell ALL. The median age was 5.5 years old (IQR 7.29). At diagnosis, 47.8% of patients were categorized as standard and 51.9% as high risk per their institutional regimen. Advanced diagnostics availability varied between modalities. MRD was evaluated in 69.1% of patients; molecular testing was available for ETV6-RUNX, BCR-ABL1, TCF3-PBX1, and KMT2A-rearranged ALL in 75-81% of patients; however, karyotyping and evaluation for iAMP21 were only performed in 42-61% of patients. Central nervous system (CNS) involvement was evaluated at diagnosis in 57.3% (n=429) patients; of these, 93.7% (n=402) were CNS 1, 1.6% (n=7) were CNS 2, 0.7% (n=11) were CNS3, 1.9% (n=8) had cranial nerve palsy, and 2.1% (n=9) results unavailable. Chemotherapy delays >2 weeks were reported in 56.0% (n=421) patients during treatment. Delays were attributed to infection in 63.2% (n=265), drug-related toxicities in 47.3% (n=198), and resource constraints, including lack of bed availability in 23.2% (n=97) of patients. The 3-year Abandonment-sensitive EFS and OS were 61.0±1.9% and 67.2±1.8%, respectively. The 3-year EFS and OS were 71.0±1.8% and 79.6±1.7%, respectively.

Discussion

This work reveals opportunities to improve survival, including addressing severe infections, treatment interruptions, and modifications due to drug shortages. In 2018, healthcare professionals across South America established the Pediatric Oncology Latin America (POLA) group in collaboration with St. Jude Children’s Research Hospital. POLA collaborators developed an evidence-based, consensus-derived, adapted treatment guideline, informed by preliminary results of this evaluation, to serve as the new standard of care for pediatric ALL in participating institutions.

Schlagwörter

Stichwörter der Autor:innen

acute lymphoblastic leukemiaconsensus-derivedlow-and middle-income countrymultinationalpediatricsurvival

Autor:innen und Institutionen

  • St. Jude Children's Research Hospital, Department of Global Pediatric Medicine, Memphis, TN, United States.
  • Departamento de Oncología Pediátrica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
  • Departamento de Hemato Oncología Pediátrica, Hospital de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de Asunción, Asunción, Paraguay.
  • Hospital Santa Cruz Caja Petrolera Salud (CPS), Hemato-Oncología Pediátrica, Santa Cruz, Bolivia.
  • Hospital SOLCA Núcleo Quito, Hemato-Oncología Pediátrica, Quito, Ecuador.
  • La Sociedad de Lucha Contra el Cáncer (SOLCA) Núcleo de Loja, Oncohematóloga Pediatra, Loja, Ecuador.

Zitieren

APA

Duffy, C., Graetz, D. E., Lopez, A. M. Z., Carrillo, A. K., Job, G., Chen, Y., Devidas, M., Leon, S. A., Bonzi, S. A., Flores, P. C., Torres, L. E., Broncano, E. H., Jaramillo, S. J., Zelada, M. O., Novoa, R. R., Samudio, A., Sánchez-Fernandez, G., Villanueva, E., Metzger, M. L., …, & Jeha, S. (2023). Retrospective analysis of outcomes for pediatric acute lymphoblastic leukemia in South American centers. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1254233

Vancouver

Duffy C, Graetz DE, Lopez AMZ, Carrillo AK, Job G, Chen Y, et al. Retrospective analysis of outcomes for pediatric acute lymphoblastic leukemia in South American centers. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1254233

BibTeX
@article{Duffy2023,
  author = {Duffy, Caitlyn and Graetz, Dylan E and Lopez, Arturo M Zapata and Carrillo, Angela K and Job, Godwin and Chen, Yichen and Devidas, Meenakshi and Leon, Sandra Alarcón and Bonzi, Sol Aponte and Flores, Pedro Cardona and Torres, Lizeth Escobar and Broncano, Eddy Hernández and Jaramillo, Soledad Jiménez and Zelada, Ma Ofelia and Novoa, Romulo Reaño and Samudio, Angelica and Sánchez-Fernandez, Gissela and Villanueva, Erika and Metzger, Monika L and Friedrich, Paola and Jeha, Sima},
  title = {Retrospective analysis of outcomes for pediatric acute lymphoblastic leukemia in South American centers},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1254233}
}
Kostenlos starten →